Abstract
Despite the increasing need for antibiotics to fight infectious diseases, fewer new antibiotics are available on the market. Unfortunately, developing a new class of antibiotics is associated with high commercial risk. Therefore, modification or combination of existing antibiotics to improve their efficacy is a promising strategy. Herein, we conjugated the antibiotic, levofloxacin, with two peptides, i.e. an antimicrobial peptide indolicidin and a cell penetrating peptide (TAT). Glycolic acid and glycine linkers were used between levofloxacin and peptides. We developed an optimized condition for coupling of levofloxacin via its carboxylic group to glycolic acid using solid phase peptide synthesis (SPPS). Antibacterial and haemolytic assays were carried out on the conjugates and only the levofloxacin-indolicidin conjugate demonstrated moderate antibacterial activity. Interestingly, physical mixture of levofloxacin and indolicidin showed improvement in the activity against Gram-positive bacteria.
Keywords: Antibiotic, levofloxacin, indolicidin, TAT peptide, conjugation.
Current Drug Delivery
Title:Levofloxacin and Indolicidin for Combination Antimicrobial Therapy
Volume: 12 Issue: 1
Author(s): Khairunnisa Abdul Ghaffar, Waleed M. Hussein, Zeinab G. Khalil, Robert J. Capon, Mariusz Skwarczynski and Istvan Toth
Affiliation:
Keywords: Antibiotic, levofloxacin, indolicidin, TAT peptide, conjugation.
Abstract: Despite the increasing need for antibiotics to fight infectious diseases, fewer new antibiotics are available on the market. Unfortunately, developing a new class of antibiotics is associated with high commercial risk. Therefore, modification or combination of existing antibiotics to improve their efficacy is a promising strategy. Herein, we conjugated the antibiotic, levofloxacin, with two peptides, i.e. an antimicrobial peptide indolicidin and a cell penetrating peptide (TAT). Glycolic acid and glycine linkers were used between levofloxacin and peptides. We developed an optimized condition for coupling of levofloxacin via its carboxylic group to glycolic acid using solid phase peptide synthesis (SPPS). Antibacterial and haemolytic assays were carried out on the conjugates and only the levofloxacin-indolicidin conjugate demonstrated moderate antibacterial activity. Interestingly, physical mixture of levofloxacin and indolicidin showed improvement in the activity against Gram-positive bacteria.
Export Options
About this article
Cite this article as:
Ghaffar Abdul Khairunnisa, Hussein M. Waleed, Khalil G. Zeinab, Capon J. Robert, Skwarczynski Mariusz and Toth Istvan, Levofloxacin and Indolicidin for Combination Antimicrobial Therapy, Current Drug Delivery 2015; 12 (1) . https://dx.doi.org/10.2174/1567201811666140910094050
DOI https://dx.doi.org/10.2174/1567201811666140910094050 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Is Metformin a Therapeutic Paradigm for Colorectal Cancer: Insight into the Molecular Pathway?
Current Drug Targets Herbal Immunomodulators - A Remedial Panacea for Designing and Developing Effective Drugs and Medicines: Current Scenario and Future Prospects
Current Drug Metabolism Modulation of Cell Death in Age-Related Diseases
Current Pharmaceutical Design Epigenetic Modulation Using Small Molecules - Targeting Histone Acetyltransferases in Disease
Current Medicinal Chemistry Progranulin Regulates Inflammation and Tumor
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry TRAIL-Based Therapeutic Approaches for the Treatment of Pediatric Malignancies
Current Medicinal Chemistry Editorial [Hot Topic: Cancer Vaccine and Immunotherapy (Executive Editor: Farid Saleh)]
Current Pharmaceutical Design Targeting Hsp90 in Non-Cancerous Maladies
Current Topics in Medicinal Chemistry Inhibitory Effects of Novel SphK2 Inhibitors on Migration of Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry HMGB1-Directed Drug Discovery Targeting Cutaneous Inflammatory Dysregulation
Current Drug Metabolism MicroRNAs: Important Epigenetic Regulators in Osteoarthritis
Current Genomics Cytotoxic Nitrobenzoyloxy-substituted Sesquiterpenes from Spongederived Endozoic Fungus Aspergillus insulicola MD10-2
Current Pharmaceutical Biotechnology From TGF-β to Cancer Therapy
Current Drug Targets CD44 and EpCAM: Cancer-Initiating Cell Markers
Current Molecular Medicine Targeted Drug Delivery Via Human Epidermal Growth Factor Receptor for Sustained Release of Allyl Isothiocyanate
Current Topics in Medicinal Chemistry Exogenous Expression of WNT7A in Leukemia-Derived Cell Lines Induces Resistance to Chemotherapeutic Agents
Anti-Cancer Agents in Medicinal Chemistry The Diversity of Epithelial Secreted Mucins
Current Organic Chemistry Targeting the p53-Family in Cancer and Chemosensitivity: Triple Threat
Current Drug Targets Apoptosis: Potential Therapeutic Targets for New Drug Discovery
Current Medicinal Chemistry Synthesis of Icaritin and β-anhydroicaritin Mannich Base Derivatives and Their Cytotoxic Activities on Three Human Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry